Ets-1 is a transcriptional mediator of oncogenic nitric oxide signaling in estrogen receptor-negative breast cancer
© Switzer et al.; licensee BioMed Central Ltd. 2012
Received: 23 April 2012
Accepted: 12 September 2012
Published: 12 September 2012
The Ets-1 transcription factor is a candidate breast cancer oncogene that regulates the expression of genes involved in tumor progression and metastasis. Ets-1 signaling has also been linked to the development of a basal-like breast cancer phenotype. We recently described a nitric oxide (NO)-induced gene signature that is associated with poor disease outcome in estrogen receptor-negative (ER-) breast cancer and contains both stem cell-like and basal-like components. Thus, we examined the role of Ets-1 in NO signaling and NO-induced phenotypes in ER- human breast cancer cells.
Promoter region analyses were performed on genes upregulated in inducible nitric oxide synthase (NOS2) high expressing tumors for Ets-binding sites. In vitro mechanisms were examined in human basal-like breast cancer cells lines. NO signaling effects were studied using either forced NOS2 expression or the use of a chemical NO-donor, diethlylenetriamine NONOate (DETANO).
Promoter region analysis of genes that are up-regulated in human ER-negative breast tumors with high NOS2 expression revealed that the Ets-binding sequence is the only common promoter element present in all of these genes, indicating that Ets-1 is the key transcriptional factor down-stream of oncogenic NOS2-signaling. Accordingly, both forced NOS2 over-expression and exposure to NO-donors resulted in significant Ets-1 transcriptional activation in ER- breast cancer cells. Functional studies showed that NO activated Ets-1 transcriptional activity via a Ras/MEK/ERK signaling pathway by a mechanism that involved Ras S-nitrosylation. RNA knock-down of Ets-1 suppressed NO-induced expression of selected basal-like breast cancer markers such as P-cadherin, S100A8, IL-8 and αβ-crystallin. Additionally, Ets-1 knock-down reduced NO-mediated cellular proliferation, matrix metalloproteinase and cathepsin B activities, as well as matrigel invasion.
These data show that Ets-1 is a key transcriptional mediator of oncogenic NO signaling that promotes the development of an aggressive disease phenotype in ER- breast cancer in an Ets-1 and Ras-dependent manner, providing novel clues of how NOS2 expression in human breast tumors is functionally linked to poor patient survival.
Inducible nitric oxide synthase (NOS2) is a pro-inflammatory enzyme generally with a key function in the innate immune response . However, NOS2 expression is up-regulated and associated with poor outcome in many human cancers, such as melanoma, glioma and colon cancer [2–4]. Recently, we reported that high NOS2 expression is a predictor of poor patient outcome in estrogen receptor-negative (ER-) breast cancer and is functionally linked to the development of a basal-like breast cancer phenotype . Basal-like tumors commonly present as the triple-negative disease, which limits the therapeutic options for the affected patients [6, 7]. Nitric oxide (NO) signaling has various oncogenic effects in cancer cells [8–11]. For example, NO activates signaling through epidermanl growth factor receptor (EGFR), PI3K/Akt, HIF-1, and Src [5, 12–15]. Together, these observations indicate that NOS2 expression may have deleterious effects in the progression of certain human cancers including ER- breast cancer. However, the molecular mechanisms by which NOS2 and NO signaling exerts an aggressive phenotype has yet to be fully determined.
Ets-1 is an oncogenic transcription factor involved in the progression of breast cancer [16–21]. Furthermore, tumor Ets-1 expression is linked to basal-like tumors and poor disease survival [19, 22, 23]. While Ets-1 is overexpressed in many tumors, its transcriptional activity is regulated at the phosphorylation level by extracellular signal-regulated protein kinases 1 and 2 (ERK1/2) [24–26]. Ets-1 regulates numerous genes involved in proliferation, angiogenesis, and metastasis . For example, Ets-1 activity upregulates vascular endothelial growth factor (VEGF)  and matrix metalloproteinases (MMP) . Thus, Ets-1 is a transcription factor that can promote an aggressive cancer cell phenotype.
Because both NOS2 and Ets-1 expression have oncogenic properties that advance the ER- disease, we investigated the functional relationship between them. This approach revealed that an Ets-binding sequence (EBS) is the only promoter element common to all genes in a previously described NOS2 expression signature for ER- breast tumors . Furthermore, overexpression of NOS2 and experimental exposure to NO resulted in Ets-1 (threonine 38) phosphorylation and increased transcriptional activity in ER- breast cancer cell lines. Further analysis showed that NO activated Ets-1 via a Ras/mitogen-activated protein kinase (MEK)/ERK signaling axis by a mechanism that involved Ras S-nitrosylation (SNO). Finally, siRNA knock-down of Ets-1 also decreased NO-induced phenotypes of disease progression. Together, these data provide novel evidence that NO signaling promotes an aggressive breast cancer phenotype by activating the oncogenic Ets-1 transcription factor.
Materials and methods
Cell culture and reagents
Human breast adenocarcinoma cell lines MDA-MB-231, MDA-MB-468 and SKBR3 (American Type Culture Collection (ATCC), Manassas, VA, USA) were cultured in RPMI medium (Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (Atlanta Biologics, Norcross, GA, USA) and 100 IU penicillin and 100 µg/ml streptomycin (Invitrogen). Cells were cultured at 37°C in 5% CO2 and passaged two to three times per week and were authenticated by short tandem repeat profiling within the past six months (ATCC). Aminoguanidine (AG) and L-arginine (L-Arg) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Farnesylthiosalicylic acid (FTS) and PD 184161 were purchased from Cayman Chemical (Ann Arbor, MI, USA). Gö6976 was purchased from EMD Chemicals (Billerica, MA, USA). Recombinant human epidermal growth factor (EGF) was purchased from R&D Systems (Minneapolis, MN, USA). Antibodies to αβ-crystalin, actin, Ets-1 and NOS2 were from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Antibodies to phospho-ERK1/2 (thr 202/tyr 204), ERK1/2 and phospho-MEK1/2 (ser 217/221) were from Cell Signaling (Danvers, MA, USA). Anti-Ras was from Thermo Scientific (Waltham, MA, USA) and anti-phospho-Ets-1 (thr 38) was purchased from Invitrogen. DETANO was generously provided by Dr. Larry Keefer (National Cancer Institute, Frederick, MD, USA). DETANO stock solutions were made in 10 mM NaOH and concentrations were determined by absorbance at 250 nm (ε = 8000 M-1·cm-1) prior to every use.
Genomic sequence analyses
The promoter sequence for each gene listed in Table 3 of Glynn et al.  was extracted using ElDorado (version 12-2010) software and analyses were performed using the RegionMiner (Release 4.2) software. Both software packages are part of the commercially available Genomatix Software Suite (V2.1) (Genomatix Software, Inc, Ann Arbor, MI, USA).
Cells were transfected with 4 µg pCMV6-XL4 (empty vector) or pCMV6-XL4-human NOS2 (NM_000625) (OriGene Technologies, Rockville, MD, USA) by electroporation using the Amaxa Nucleofector kit V (Lonza, Walkersville, MD, USA) and then grown for 48 hours under normal conditions before further treatment or analysis.
Western blotting was performed by standard procedures. Cells were lysed on ice with cold lysis buffer (Tris-HCl pH 8.0 (50 mM), NaCl (150 mM), NP-40 (1%), ethylenediaminetetraacetic acid (EDTA, 1 mM), NaF (50 mM), Na3VO4 (10 mM), phenylmethylsulfonyl fluoride (PMSF, 1 mM) and protease inhibitor cocktail (EMD Chemicals)). Images were recorded on a FluoroChem SP system using AlphaEase FC software (Alpha Innotech, San Leandro, CA, USA).
Ets-1 transcriptional activity was performed by transiently transfecting cells with 750 ng of Ets-luciferase reporter plasmid expressing firefly luciferase (Panomics, Santa Clara, CA, USA) and 250 ng pGL4.70 plasmid expressing renella luciferase (Promega, Madison, WI, USA) using Lipofectamine LTX reagent for six hours at 37°C. After transfection, cell culture media was replaced with serum-free (D)MEM containing EGF (20 ng/mL), DETANO and inhibitors. Cells were incubated for 18 hours and luciferase activity was measured using the Dual-luciferase assay kit (Promega). Relative luminescent units (RLU) were measured using a Glomax 96-well plate luminometer (Promega) and data were normalized to fold change from untreated control cells. Data represent mean normalized RLU ± standard deviation (SD).
Ras activation and S-nitrosylation
Relative Ras activation was determined using the Ras binding domain (RBD)-pull-down assay kit (Thermo Scientific). Briefly, cell lysate was incubated with RBD-agarose beads. Immunoprecipitated active Ras was eluted by boiling in 4X-lithium dodecyl sulfate (LDS) sample buffer. Active Ras and total cellular Ras were measured by western blot. Activation of Ras is shown as mean fold increase compared to untreated cells ± SD. Ras was immunoprecipitated using Protein G-Dynabeads (Invitrogen) conjugated with monoclonal mouse anti-Ras and assayed with the S-Nitrosylated Protein Detection Kit (Cayman Chemical) as instructed by the manufacturer. Procedures were performed under low ambient light to diminish Ras-SNO decomposition.
Cells (1 × 106/100 µL) were transfected with 400 nM total siRNA by electroporation using the Amaxa Nucleofector Kit V. Cells were grown in RPMI + 10% FBS for 48 hours before further treatment or analysis. Human Ets-1 siGENOME SMARTpool (Thermo Scientific) oligonucleotide sequences: 5'-GAUAAAUCCUGUCAGUCUU-3'; 5'-GGACCGUGCUGACCUCAAU-3'; 5'-GGAAUUACUCACUGAUAAA-3' and 5'-GCAUAGAGAGCUACGAUAG-3'. Control siGENOME non-targeting siRNA pool (Thermo Scientific) sequences: 5'-UAGCGACUAAACACAUCAA-3'; 5'-UAAGGCUAUGAAGAGAUAC-3'; 5'-AUGUAUUGGCCUGUAUUAG-3' and 5'-AUGAACGUGAAUUGCUCAA-3'. Ets-1 knock-down was verified at the protein level by western blot.
Cells were treated with or without 0.5 mM DETANO in serum-free RPMI containing 20 µM bromodeoxyuridine (BrDU) for 24 hours. Using the BrDU ELISA kit (Cell Signaling), cells were then fixed, washed and BrDU incorporation was determined by incubating mouse anti-BrDU followed by anti-mouse-horseradish peroxidase (HRP) secondary. Absorbance data are normalized to fold-increase compared to untreated controls and are shown as mean fold change ± SD.
Cathepsin B activity
Cathepsin B Activity Fluorometric Assay Kit (Abcam, Cambridge, MA, USA) was used as instructed. Briefly, treated cells were lysed and samples were incubated with substrate Acetyl-arginine-arginine-amino-4-trifluoromethyl coumarin (Ac-RR-AFC). Released AFC was measured by fluorescence (400 nm excitation/505 nm emission). Data are normalized to fold change compared to untreated control cells and are shown as mean ± SD.
MMP isoform expression was measured by spot-ELISA (R&D Systems) as instructed by the manufacturer. Briefly, conditioned medium was diluted and incubated in wells containing absorbed MMP antibodies. After washing, HRP-secondary antibody was applied and resulting spots were imaged by chemiluminescence as described above.
Total MMP activity was measured by the MCa assay as previously described . Briefly, conditioned medium was incubated with 10 µM MCa peptide [7-methoxycoumarin-4-acetyl-Pro-Leu-Gly-Leu-β-(2,4dinitrophenylamino)Ala-Ala-Arg-NH2] (Sigma-Aldrich). Fluorescence intensity was measured (328 nm excitation/392 nm emission) and normalized to total cellular protein. Data are represented as mean RFU per microgram protein ± SD.
Cellular invasion assays were performed as previously described . Briefly, MDA-MB-231 cells were seeded into the top chamber of transwell plates with 8 mm pores with a thin film of matrigel (BD Biosciences, San Jose, CA, USA) in serum-free RPMI containing the indicated concentration of DETANO and allowed to invade towards RPMI containing 5% FBS for 24 hours. Data represent mean number of invading cells ± SD.
Data analyses were performed using Prism 4 software (GraphPad Software, Inc., La Jolla, CA, USA). Statistical significance was calculated using one-way analysis of variance (ANOVA) analyses with Dunnett's post-test or unpaired t-test. Significance was determined with P values less than 0.05 or 0.01 as stated in the figure legends.
NOS2 signals through Ets-1 in human ER- breast tumors
Recently, we reported that NOS2 expression is significantly associated with poor survival in ER- breast cancer and that high NOS2 expression is associated with a distinct gene expression profile similar to the basal-like phenotype . Further analysis of the gene signature revealed that the Ets-binding site (EBS) is the only promoter element common to all 46 up-regulated genes [see Additional file 1: Table S1]. To further examine the enrichment of EBS-regulated genes in high NOS2 expressing ER- tumors, bulk tumor tissue was also analyzed using the Gene Set Analysis against the TRANSFAC database. A significant enrichment of genes with EBS was found among the genes that were up-regulated in the NOS2 high tumors, confirming that NOS2 and Ets-regulated genes are correlated in ER- breast tumors. Thus, we examined the role of NOS2 activity and NO signaling in the activation of the Ets-1 transcription factor in human ER- breast cancer cell lines.
NOS2 and NO increases Ets-1 transcriptional activity
Because NOS2 expression resulted in Ets-1 (thr 38) phosphorylation, we also examined the effect of NO signaling on Ets-1 activation in human ER- breast cancer cell lines treated with NO releasing compounds. Using the chemical NO-donor DETANO, the effect of NO on Ets-1 (thr 38) phosphorylation in MDA-MB-468, MDA-MB-231 and SUM159 cell lines was examined. The applied donor concentrations generate actual NO concentrations that are in the physiological nanomolar concentration range because of the slow release rate of NO from this donor [see Additional file 2: Figure S1] . DETANO induced significant increases in Ets-1 (thr 38) phosphorylation in all three cell lines in a concentration-dependent manner as compared to untreated serum-starved controls (Figure 1B). The NO-donor at 0.5 mM induced a level of Ets-1 (thr 38) phosphorylation similar to the stimulation of MDA-MB-468 cells with EGF (10 ng/ml). EGF did not result in an increase of Ets-1 (thr 38) phosphorylation in MDA-MB-231 or SUM159 cell lines, which exhibit relatively low EGFR expression and EGF-induced tyrosine 1173 phosphorylation compared to MDA-MB-468 cells [see Additional file 3: Figure S2]. Additionally, similar results were observed in the ER-/HER2+ SKBR3 cell line [see Additional file 4: Figure S3]. Our data indicate that NOS2 phosphorylates Ets-1 via NO production and subsequent NO signaling.
To examine the effect of NOS2 expression on Ets-1 transcriptional activity, MDA-MB-468 cells were transfected with a NOS2 expression plasmid and then transiently transfected with an Ets-luciferase reporter plasmid. Cells were then incubated in serum-free media supplemented with L-Arg or AG. NOS2 expression resulted in a significant increase in luciferase reporter activity when incubated with L-Arg; however, this effect was not observed in the presence of the NOS2 inhibitor AG, indicating that NO release resulted in Ets-1 transcriptional activation (Figure 1C). To examine the effect of NO signaling on Ets-1 transcriptional activity, MDA-MB-468 and MDA-MB-231 cells were transiently transfected with an Ets-luciferase reporter plasmid and treated with EGF or DETANO in serum-free media. EGF caused a significant increase in luciferase activity compared to untreated controls in the MDA-MB-468 cells, but not in MDA-MB-231 cells, reminiscent of the Ets-1 (thr 38) phosphorylation findings for these cell lines (Figure 1D). DETANO caused a concentration-dependent increase in luciferase activity and the effect was most significant at 0.3 and 0.5 mM in both MDA-MB-468 and MDA-MB-231 cells. These data show that NOS2, via NO signaling, increases Ets-1 transcriptional activity in ER- breast cancer cells.
NO activates Ets-1 viaa Ras/MEK/ERK signaling pathway
To examine the role of Ras in mediating the NO activation of the MEK/ERK/Ets-1 signaling pathway, MDA-MB-468 cells were treated with EGF or 0.5 mM DETANO with or without the Ras inhibitor FTS. FTS blocks Ras association with the cellular membrane and renders Ras protein susceptible to proteasomal degradation . EGF and DETANO resulted in Ets-1 (thr 38) phosphorylation; however, this signaling effect was not observed in the presence of FTS (Figure 3E). Furthermore, FTS treatment resulted in decreased Ras protein levels, indicating that Ras signaling is critical for NO to increase Ets-1 (thr 38) phosphorylation. An alternative activator of MEK-1/2 signaling is protein kinase Cα (PKCα) [38–40]. To examine the role of PKCα on NO activation of MEK/ERK/Ets-1 signaling, cells were treated with EGF or 0.5 mM DETANO and with or without the PKCα inhibitor Gö 6976. The phosphorylation of Ets-1 by NO was not altered by Gö 6976 (Figure 3F), suggesting that NO activates Ets-1 via a PKCα-independent mechanism.
To examine the role of Ras and PKCα on NO-mediated Ets-1 transcriptional activity, MDA-MB-468 cells were transfected with an Ets-luciferase reporter plasmid and treated with 0.5 mM DETANO alone or in combination with either Gö 6976 or FTS. Consistent with the Ets-1 phosphorylation results, FTS blocked the effect of NO to increase Ets-1 transcriptional activity, while Gö 6976 had no effect on luciferase activity (Figure 3G). These data suggest that NO activates Ets-1 signaling and its transcriptional activity via a Ras/MEK/ERK signaling pathway and not via PKCα activation (Figure 3H).
NO and Ets-1 contribute to an aggressive basal-like phenotype
Ets-1 regulates the expression of various proteases that are critical to matrix reorganization and cancer cell invasion . Therefore, the role of NO/Ets-1 signaling on cathepsin B (CTSB) was examined. CTSB expression and activity was measured in extracts from cells transfected with Ets-1 siRNA and treated with or without 0.5 mM DETANO and compared to cells transfected with control siRNA. CTSB expression was only modestly increased in DETANO-treated control cells but was markedly reduced in cells transfected with Ets-1 siRNA (Figure 4A and 4B). In contrast to the CTSB expression levels, CTSB activity significantly increased in DETANO-treated cells when compared to untreated cells (Figure 4D). However, CTSB activity was significantly reduced in cells transfected with Ets-1 siRNA compared to control siRNA in both DETANO-treated and untreated conditions (Figure 4E). These results show that NO increases CTSB expression and activity via Ets-1 signaling.
Our study made the novel observation that the oncogenic transcription factor Ets-1 is a critical mediator of NOS2 and NO-induced signaling in breast cancer and thus, this study provides a molecular mechanism that at least partly explains the oncogenic effects of NO in ER- breast cancer. Moreover, the robust association between NOS2 expression and up-regulation of genes with EBS transcriptional activation sites in microdissected and bulk tumor epithelia indicates that Ets-1 is a significant in vivo mediator of NOS2 signaling in human ER- breast tumors. NOS2 expression in ER- breast tumors is associated with poor patient outcomes and a basal-like phenotype , linking NO signaling to this poor outcome and highly metastatic phenotype [6, 45]. NO activation of Ets-1 resulted in the cellular expression of basal-like markers (P-cadherin, S100A8, IL-8 and αβ-crystallin) [46–48] as well as molecules associated with the metastatic process (CTSB and MMP-7) [49, 50] indicating that this signaling mechanism contributes to the observed clinical features of aggressive ER- breast cancers that overexpress NOS2. In addition to the Ras/MEK/ERK/Ets-1 signaling pathway elucidated here, NOS2 and NO activate multiple oncogenic signaling pathways such as EGFR, PI3K/Akt, c-Myc, HIF-1a, NF-kB and Src . Furthermore, S100A8 and MMPs are potential targets of SNO highlighting the multifaceted effects of NO signaling in cancer cell biology. Therefore, the activation of Ras/Ets-1 is a contributing signaling axis induced by oncogenic levels of NO [8, 51]. These observations strongly point to NOS2 as a potential comprehensive driver of aggressive metastatic tumors and further suggest that NOS2 inhibition or blunting of NO/SNO signaling is a potential therapeutic target for basal-like breast tumors. This is of significant clinical impact as basal-like tumors commonly express the triple-negative phenotype and, therefore, currently lack therapeutic targets [6, 7].
The data shown here indicate that Ras activation by NO has signaling effects in human breast cancer and this signaling mechanism may represent a major target of NO signaling in cancer biology. While mutated and constitutively active Ras is often observed in human malignancy, breast tumors harboring Ras mutations are rare, accounting for >5% of all breast tumors [52, 53]. Wild-type Ras-SNO modification and activation has been characterized; however, the resulting signaling effects in human cancer have not been thoroughly investigated. The involvement of Ras SNO described here in ER- breast cancer cells is consistent with previous reports in T lymphocytes and lung tumors [54, 55]. Ras activation by NO in breast cancer cells has been described to proceed in a cGMP-independnet mechanism and our data showing NO-mediated SNO of Ras is consistent with this previous report . Our finding that NO activation of Ras, via SNO results in Ets-1 activation suggests that other Ras-mediated pathways may also activated by NO in human cancer.
We propose that the NO/Ets-1 signaling axis first described here may promote disease progression in other tumors that overexpress NOS2, such as glioma and melanoma [2, 57], and tumors with impaired SNO metabolism, such as lung and hepatocellular carcinoma [55, 58]. Ets-1 has also been linked to melanoma and lung tumor metastasis [59, 60]. Furthermore, our data showing that NO results in a MEK/ERK/Ets-1 signaling cascade in ER-/HER2+ SKBR3 cells [see Additional file 4: Figure S3] suggest that high NOS2 expression and NO signaling may induce proliferative and aggressive phenotypes in HER2+ breast cancer. Together, these data further strengthen the proposed linkage between NO and Ets-1 signaling and suggest that their interaction is a major promoter of tumor metastasis and requires further investigation.
In summary, NO signaling results in the activation of the oncogenic transcription factor Ets-1, which is critical for the basal-like breast cancer phenotype associated with tumor NOS2 expression. This effect of NO is mediated by Ras-SNO modification and subsequent MEK/ERK signaling to phosphorylate Ets-1 (thr 38). Activation of Ets-1 by NO resulted in the increased expression of the basal-like markers P-cadherin, S100A8, IL-8 and αβ-crystallin, which mechanistically links two prognostic markers of poor basal-like patient survival [5, 23]. Furthermore, NO activation of Ets-1 resulted in increased expression and activity of proteases critical for tumor metastasis, MMPs and CTSB, and resulted in increased cancer cell invasion and proliferation. These data imply a molecular mechanism that elucidates the aggressive basal-like phenotype induced by NOS2 and NO signaling and provides a potential therapeutic target for triple negative/basal-like breast cancer.
cyclic guanosine monophosphate
(Dulbecco's) modified Eagle's medium
epidermal growth factor
epidermal growth factor receptor
enzyme-linked immunosorbent assay
estrogen receptor-alpha negative
extracellular signal-regulated kinases
erythroblastosis virus E26 oncogene homolog 1
mitogen-activated protein kinase
inducible nitric oxide synthase
protein kinase Cα
relative luminescent units
small interfering RNA
vascular endothelial growth factor.
The authors thank Dr. Atsushi Terunuma (NCI, NIH) for assistance with genetic analyses. This research was supported by the Intramural Research Program of the NIH, National Cancer Institute.
- Wink DA, Hines HB, Cheng RYS, Switzer CH, Flores-Santana W, Vitek MP, Ridnour LA, Colton CA: Nitric oxide and redox mechanisms in the immune response. J Leukoc Biol. 2011, 89: 873-891. 10.1189/jlb.1010550.View ArticleGoogle Scholar
- Eyler CE, Wu Q, Yan K, MacSwords JM, Chandler-Militello D, Misuraca KL, Lathia JD, Forrester MT, Lee J, Stamler JS, Goldman SA, Bredel M, McLendon RE, Sloan AE, Hjelmeland AB, Rich JN: Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell. 2011, 146: 53-66. 10.1016/j.cell.2011.06.006.View ArticleGoogle Scholar
- Cheng R, Ridnour LA, Glynn SA, Switzer CH, Flores-Santana W, Hussain P, Thomas DD, Ambs S, Harris CC, Wink DA: Nitric Oxide and Cancer: An Overview. Nitric Oxide (NO) and Cancer. Edited by: Bonavida B. 2010, New York: Springer, 3-20.View ArticleGoogle Scholar
- Ekmekcioglu S, Tang CH, Grimm EA: NO news is not necessarily good news in cancer. Curr Cancer Drug Targets. 2005, 5: 103-115. 10.2174/1568009053202072.View ArticleGoogle Scholar
- Glynn SA, Boersma BJ, Dorsey TH, Yi M, Yfantis HG, Ridnour LA, Martin DN, Switzer CH, Hudson RS, Wink DA, Lee DH, Stephens RM, Ambs S: Increased NOS2 predicts poor survival in estrogen receptor-negative breast cancer patients. J Clin Invest. 2010, 120: 3843-3854. 10.1172/JCI42059.View ArticleGoogle Scholar
- Reis-Filho JS, Tutt ANJ: Triple negative tumours: a critical review. Histopathology. 2008, 52: 108-118.View ArticleGoogle Scholar
- Rakha EA, Reis-Filho JS, Ellis IO: Basal-like breast cancer: a critical review. J Clin Oncol. 2008, 26: 2568-2581. 10.1200/JCO.2007.13.1748.View ArticleGoogle Scholar
- Switzer CH, Glynn SA, Ridnour LA, Cheng RYS, Vitek MP, Ambs S, Wink DA: Nitric oxide and protein phosphatase 2A provide novel therapeutic opportunities in ER-negative breast cancer. Trends Pharmacol Sci. 2011, 32: 644-651. 10.1016/j.tips.2011.07.001.View ArticleGoogle Scholar
- Thomas DD, Ridnour LA, Isenberg JS, Flores-Santana W, Switzer CH, Donzelli S, Hussain P, Vecoli C, Paolocci N, Ambs S, Colton CA, Harris CC, Roberts DD, Wink DA: The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med. 2008, 45: 18-31. 10.1016/j.freeradbiomed.2008.03.020.View ArticleGoogle Scholar
- Pervin S, Chaudhuri G, Singh R: NO to breast: when, why and why not?. Curr Pharm Des. 2010, 16: 451-462. 10.2174/138161210790232130.View ArticleGoogle Scholar
- Fukumura D, Kashiwagi S, Jain RK: The role of nitric oxide in tumour progression. Nat Rev Cancer. 2006, 6: 521-534. 10.1038/nrc1910.View ArticleGoogle Scholar
- Prueitt RL, Boersma BJ, Howe TM, Goodman JE, Thomas DD, Ying L, Pfiester CM, Yfantis HG, Cottrell JR, Lee DH, Remaley AT, Hofseth LJ, Wink DA, Ambs S: Inflammation and IGF-I activate the Akt pathway in breast cancer. Int J Cancer. 2007, 120: 796-805. 10.1002/ijc.22336.View ArticleGoogle Scholar
- Thomas DD, Espey MG, Ridnour LA, Hofseth LJ, Mancardi D, Harris CC, Wink DA: Hypoxic inducible factor 1a, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci USA. 2004, 101: 8894-8899. 10.1073/pnas.0400453101.View ArticleGoogle Scholar
- Rahman MA, Senga T, Ito S, Hyodo T, Hasegawa H, Hamaguchi M: S-nitrosylation at cysteine 498 of c-Src tyrosine kinase regulates nitric oxide-mediated cell invasion. J Biol Chem. 2010, 285: 3806-3814. 10.1074/jbc.M109.059782.View ArticleGoogle Scholar
- Lee H-C, An S, Lee H, Woo S-H, Jin H-O, Seo S-K, Choe T-B, Yoo D-H, Lee S-J, Hong Y-J, Park M-J, Rhee C-H, Park I-C, Hong S-I: Activation of epidermal growth factor receptor and its downstream signaling pathway by nitric oxide in response to ionizing radiation. Mol Cancer Res. 2008, 6: 996-1002. 10.1158/1541-7786.MCR-08-0113.View ArticleGoogle Scholar
- Hahne JC, Okuducu AF, Kaminski A, Florin A, Soncin F, Wernert N: Ets-1 expression promotes epithelial cell transformation by inducing migration, invasion and anchorage-independent growth. Oncogene. 2005, 24: 5384-5388. 10.1038/sj.onc.1208761.View ArticleGoogle Scholar
- Furlan A, Vercamer C, Desbiens X, Pourtier A: Ets-1 triggers and orchestrates the malignant phenotype of mammary cancer cells within their matrix environment. J Cell Physiol. 2008, 215: 782-793. 10.1002/jcp.21360.View ArticleGoogle Scholar
- Turner DP, Findlay VJ, Moussa O, Watson DK: Defining ETS transcription regulatory networks and their contribution to breast cancer progression. J Cell Biochem. 2007, 102: 549-559. 10.1002/jcb.21494.View ArticleGoogle Scholar
- Mylona EE, Alexandrou PT, Giannopoulou IA, Rafailidis PI, Markaki S, Keramopoulos A, Nakopoulou LL: Study of the topographic distribution of ets-1 protein expression in invasive breast carcinomas in relation to tumor phenotype. Cancer Detect Prev. 2006, 30: 111-117. 10.1016/j.cdp.2006.03.006.View ArticleGoogle Scholar
- Lincoln DW 2nd, Bove K: The transcription factor Ets-1 in breast cancer. Front Biosci. 2005, 10: 506-511. 10.2741/1546.View ArticleGoogle Scholar
- Buggy Y, Maguire TM, McGreal G, McDermott E, Hill AD, O'Higgins N, Duffy MJ: Overexpression of the Ets-1 transcription factor in human breast cancer. Br J Cancer. 2004, 91: 1308-1315. 10.1038/sj.bjc.6602128.View ArticleGoogle Scholar
- Span PN, Manders P, Heuvel JJ, Thomas CM, Bosch RR, Beex LV, Sweep CG: Expression of the transcription factor Ets-1 is an independent prognostic marker for relapse-free survival in breast cancer. Oncogene. 2002, 21: 8506-8509. 10.1038/sj.onc.1206040.View ArticleGoogle Scholar
- Bosman JD, Yehiely F, Evans JR, Cryns VL: Regulation of alphaB-crystallin gene expression by the transcription factor Ets1 in breast cancer. Breast Cancer Res Treat. 2010, 119: 63-70. 10.1007/s10549-009-0330-4.View ArticleGoogle Scholar
- Yang BS, Hauser CA, Henkel G, Colman MS, Van Beveren C, Stacey KJ, Hume DA, Maki RA, Ostrowski MC: Ras-mediated phosphorylation of a conserved threonine residue enhances the transactivation activities of c-Ets1 and c-Ets2. Mol Cell Biol. 1996, 16: 538-547.View ArticleGoogle Scholar
- Wasylyk C, Bradford AP, Gutierrez-Hartmann A, Wasylyk B: Conserved mechanisms of Ras regulation of evolutionary related transcription factors, Ets1 and Pointed P2. Oncogene. 1997, 14: 899-913. 10.1038/sj.onc.1200914.View ArticleGoogle Scholar
- Paumelle R, Tulasne D, Kherrouche Z, Plaza S, Leroy C, Reveneau S, Vandenbunder B, Fafeur V: Hepatocyte growth factor/scatter factor activates the ETS1 transcription factor by a RAS-RAF-MEK-ERK signaling pathway. Oncogene. 2002, 21: 2309-2319. 10.1038/sj.onc.1205297.View ArticleGoogle Scholar
- Iwasaka C, Tanaka K, Abe M, Sato Y: Ets-1 regulates angiogenesis by inducing the expression of urokinase-type plasminogen activator and matrix metalloproteinase-1 and the migration of vascular endothelial cells. J Cell Physiol. 1996, 169: 522-531. 10.1002/(SICI)1097-4652(199612)169:3<522::AID-JCP12>3.0.CO;2-7.View ArticleGoogle Scholar
- Chen Z, Fisher RJ, Riggs CW, Rhim JS, Lautenberger JA: Inhibition of vascular endothelial growth factor-induced endothelial cell migration by ETS1 antisense oligonucleotides. Cancer Res. 1997, 57: 2013-2019.Google Scholar
- Sahin A, Velten M, Pietsch T, Knuefermann P, Okuducu AF, Hahne JC, Wernert N: Inactivation of Ets 1 transcription factor by a specific decoy strategy reduces rat C6 glioma cell proliferation and mmp-9 expression. Int J Mol Med. 2005, 15: 771-776.Google Scholar
- Ridnour LA, Windhausen AN, Isenberg JS, Yeung N, Thomas DD, Vitek MP, Roberts DD, Wink DA: Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways. Proc Natl Acad Sci USA. 2007, 104: 16898-16903. 10.1073/pnas.0702761104.View ArticleGoogle Scholar
- Keefer LK, Nims RW, Davies KM, Wink DA: "NONOates" (1-substituted diazen-1-ium-1,2-diolates) as nitric oxide donors: convenient nitric oxide dosage forms. Methods Enzymol. 1996, 268: 281-293.View ArticleGoogle Scholar
- Kolch W: Meaningful relationships: the regulation of the Ras/Raf/MEK/ERK pathway by protein interactions. Biochem J. 2000, 351: 289-305. 10.1042/0264-6021:3510289.View ArticleGoogle Scholar
- Lander HM, Hajjar DP, Hempstead BL, Mirza UA, Chait BT, Campbell S, Quilliam LA: A molecular redox switch on p21(ras). Structural basis for the nitric oxide-p21(ras) interaction. J Biol Chem. 1997, 272: 4323-4326. 10.1074/jbc.272.7.4323.View ArticleGoogle Scholar
- Mirza UA, Chait BT, Lander HM: Monitoring reactions of nitric oxide with peptides and proteins by electrospray ionization-mass spectrometry. J Biol Chem. 1995, 270: 17185-17188. 10.1074/jbc.270.29.17185.View ArticleGoogle Scholar
- Jaffrey SR, Snyder SH: The biotin switch method for the detection of S-nitrosylated proteins. Sci STKE. 2001, 2001: pl1-Google Scholar
- Wink DA, Nims RW, Darbyshire JF, Christodoulou D, Hanbauer I, Cox GW, Laval F, Laval J, Cook JA, Krishna MC: Reaction kinetics for nitrosation of cysteine and glutathione in aerobic nitric oxide solutions at neutral pH. Insights into the fate and physiological effects of intermediates generated in the NO/O2 reaction. Chem Res Toxicol. 1994, 7: 519-525. 10.1021/tx00040a007.View ArticleGoogle Scholar
- Haklai R, Weisz MG, Elad G, Paz A, Marciano D, Egozi Y, Ben-Baruch G, Kloog Y: Dislodgment and accelerated degradation of Ras. Biochemistry. 1998, 37: 1306-1314. 10.1021/bi972032d.View ArticleGoogle Scholar
- Lindemann RK, Braig M, Ballschmieter P, Guise TA, Nordheim A, Dittmer J: Protein kinase Calpha regulates Ets1 transcriptional activity in invasive breast cancer cells. Int J Oncol. 2003, 22: 799-805.Google Scholar
- Kolch W, Heidecker G, Kochs G, Hummel R, Vahidi H, Mischak H, Finkenzeller G, Marme D, Rapp UR: Protein kinase C[alpha] activates RAF-1 by direct phosphorylation. Nature. 1993, 364: 249-252. 10.1038/364249a0.View ArticleGoogle Scholar
- Vetter M, Blumenthal SG, Lindemann RK, Manns J, Wesselborg S, Thomssen C, Dittmer J: Ets1 is an effector of protein kinase C[alpha] in cancer cells. Oncogene. 2005, 24: 650-661. 10.1038/sj.onc.1208234.View ArticleGoogle Scholar
- Dittmer J: The biology of the Ets1 proto-oncogene. Mol Cancer. 2003, 2: 29-10.1186/1476-4598-2-29.View ArticleGoogle Scholar
- Behrens P, Rothe M, Wellmann A, Krischler J, Wernert N: The Ets-1 transcription factor is up-regulated together with MMP 1 and MMP 9 in the stroma of pre-invasive breast cancer. J Pathol. 2001, 194: 43-50. 10.1002/path.844.View ArticleGoogle Scholar
- Sasaki H, Yukiue H, Moiriyama S, Kobayashi Y, Nakashima Y, Kaji M, Kiriyama M, Fukai I, Yamakawa Y, Fujii Y: Clinical significance of matrix metalloproteinase-7 and Ets-1 gene expression in patients with lung cancer. J Surg Res. 2001, 101: 242-247. 10.1006/jsre.2001.6279.View ArticleGoogle Scholar
- Duffy MJ, Maguire TM, Hill A, McDermott E, O'Higgins N: Metalloproteinases: role in breast carcinogenesis, invasion and metastasis. Breast Cancer Res. 2000, 2: 252-257. 10.1186/bcr65.View ArticleGoogle Scholar
- Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lønning PE, Børresen-Dale A-L: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874. 10.1073/pnas.191367098.View ArticleGoogle Scholar
- Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N, Fekairi S, Xerri L, Jacquemier J, Birnbaum D, Bertucci F: Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene. 2006, 25: 2273-2284. 10.1038/sj.onc.1209254.View ArticleGoogle Scholar
- Rody A, Karn T, Liedtke C, Pusztai L, Ruckhaeberle E, Hanker L, Gaetje R, Solbach C, Ahr A, Metzler D, Schmidt M, Muller V, Holtrich U, Kaufmann M: A clinically relevant gene signature in triple negative and basal-like breast cancer. Breast Cancer Res. 2011, 13: R97-10.1186/bcr3035.View ArticleGoogle Scholar
- Sitterding SM, Wiseman WR, Schiller CL, Luan C, Chen F, Moyano JV, Watkin WG, Wiley EL, Cryns VL, Diaz LK: AlphaB-crystallin: a novel marker of invasive basal-like and metaplastic breast carcinomas. Ann Diagn Pathol. 2008, 12: 33-40. 10.1016/j.anndiagpath.2007.02.004.View ArticleGoogle Scholar
- Withana NP, Blum G, Sameni M, Slaney C, Anbalagan A, Olive MB, Bidwell BN, Edgington L, Wang L, Moin K, Sloane BF, Anderson RL, Bogyo MS, Parker BS: Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res. 2012, 72: 1199-1209. 10.1158/0008-5472.CAN-11-2759.View ArticleGoogle Scholar
- Nomura T, Katunuma N: Involvement of cathepsins in the invasion, metastasis and proliferation of cancer cells. J Med Invest. 2005, 52: 1-9. 10.2152/jmi.52.1.View ArticleGoogle Scholar
- Ridnour LA, Thomas DD, Switzer C, Flores-Santana W, Isenberg JS, Ambs S, Roberts DD, Wink DA: Molecular mechanisms for discrete nitric oxide levels in cancer. Nitric Oxide. 2008, 19: 73-76. 10.1016/j.niox.2008.04.006.View ArticleGoogle Scholar
- von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE, Boss GR: Ras activation in human breast cancer. Breast Cancer Res Treat. 2000, 62: 51-62. 10.1023/A:1006491619920.View ArticleGoogle Scholar
- Sanchez-Munoz A, Gallego E, de Luque V, Perez-Rivas LG, Vicioso L, Ribelles N, Lozano J, Alba E: Lack of evidence for KRAS oncogenic mutations in triple-negative breast cancer. BMC Cancer. 2010, 10: 136-10.1186/1471-2407-10-136.View ArticleGoogle Scholar
- Deora AA, Hajjar DP, Lander HM: Recruitment and activation of Raf-1 kinase by nitric oxide-activated Ras. Biochemistry. 2000, 39: 9901-9908. 10.1021/bi992954b.View ArticleGoogle Scholar
- Marozkina NV, Wei C, Yemen S, Wallrabe H, Nagji AS, Liu L, Morozkina T, Jones DR, Gaston B: S-Nitrosoglutathione reductase in human lung cancer. Am J Respir Cell Mol Biol. 2012, 46: 63-70. 10.1165/rcmb.2011-0147OC.View ArticleGoogle Scholar
- Pervin S, Singh R, Hernandez E, Wu G, Chaudhuri G: Nitric oxide in physiologic concentrations targets the translational machinery to increase the proliferation of human breast cancer cells: involvement of mammalian target of rapamycin/eIF4E pathway. Cancer Res. 2007, 67: 289-299. 10.1158/0008-5472.CAN-05-4623.View ArticleGoogle Scholar
- Ekmekcioglu S, Ellerhorst J, Smid CM, Prieto VG, Munsell M, Buzaid AC, Grimm EA: Inducible nitric oxide synthase and nitrotyrosine in human metastatic melanoma tumors correlate with poor survival. Clin Cancer Res. 2000, 6: 4768-4775.Google Scholar
- Wei W, Li B, Hanes MA, Kakar S, Chen X, Liu L: S-Nitrosylation from GSNOR deficiency impairs DNA repair and promotes hepatocarcinogenesis. Sci Transl Med. 2: 19ra13-
- Yamaguchi E, Nakayama T, Nanashima A, Matsumoto K, Yasutake T, Sekine I, Nagayasu T: Ets-1 proto-oncogene as a potential predictor for poor prognosis of lung adenocarcinoma. Tohoku J Exp Med. 2007, 213: 41-50. 10.1620/tjem.213.41.View ArticleGoogle Scholar
- Rothhammer T, Hahne JC, Florin A, Poser I, Soncin F, Wernert N, Bosserhoff AK: The Ets-1 transcription factor is involved in the development and invasion of malignant melanoma. Cell Mol Life Sci. 2004, 61: 118-128. 10.1007/s00018-003-3337-8.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.